Evaluation of a Functional Lymphocyte Test (QuantiFERON Monitor®) as a Prognostic Marker for Acute Community-acquired Pneumonia (LYMPHONIE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03505281|
Recruitment Status : Recruiting
First Posted : April 23, 2018
Last Update Posted : November 15, 2018
Lower respiratory infections, or pneumonia, remain the third leading cause of death worldwide, despite progress in vaccinating at-risk populations and improved resuscitation techniques.
Research shows that immune defences are weakened during severe infections. This immune weakening could alter resistance to bacterial infection and facilitate death, but also facilitate the onset of secondary infections.
Through this study, investigators wish to evaluate a biomedical test (derived from a blood sample - Quantiferon Monitor test), aimed at measuring the immune response of certain immune cells (lymphocytes).
The objective of the study is to determine whether this test can predict the occurrence of death during pneumonia.
If this hypothesis is verified, it would make it possible to use this test as a marker to identify patients at risk of death, and would open up new therapeutic prospects in order to provide patients with severe pneumonia with a treatment that stimulates their immune defences.
|Condition or disease||Intervention/treatment|
|Pneumonia||Biological: Blood samples|
|Study Type :||Observational|
|Estimated Enrollment :||56 participants|
|Official Title:||Evaluation of a Functional Lymphocyte Test (QuantiFERON Monitor®) as a Prognostic Marker for Acute Community-acquired Pneumonia|
|Actual Study Start Date :||November 5, 2018|
|Estimated Primary Completion Date :||June 2020|
|Estimated Study Completion Date :||June 2020|
- Biological: Blood samples
Collection of two additional tubes at the time of a blood test necessary for patient follow-up.
- Death [ Time Frame: 30 days following hospitalization for community-acquired pneumonia ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03505281
|Contact: Mathieu BLOTemail@example.com|
|Chu Dijon Bourogne||Recruiting|
|Dijon, France, 21000|
|Contact: Mathieu BLOT 03.80.29.33.05 firstname.lastname@example.org|